|
Re: New, effective and less toxic therapeutic option for patients with HER2-positive
Overall Survival was an end-point in Emilia trial, it favored participants in T-DM1 arm, people in the lapatinib and Xeloda arm were offered the option to receive trastuzumab emtansine
http://www.roche.com/media/media_rel...012-10-01b.htm |